The NCPE are seeking feedback on our updated Patient Submission Process. Closing date for comments is 30th April 2018 http://www.ncpe.ie/submission-process/public-consultation/
The NCPE recommends that blinatumomab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
The NCPE does not recommend reimbursement of Teduglutide (Revestive®) for the treatment of patients aged 1 year and above with short bowel syndrome.